ETNB - 89bio Inc Debt to Book Capitalization Ratio

The 89bio, Inc. (ETNB) price chart on the GURU.Markets platform illustrates the price action of the asset, which is currently valued at 0.07. The business focuses on developing Pegozafermin, an innovative treatment for fatty liver disease based on modified FGF21. The development model anticipates high margins driven by formula patenting, while supply reliability is ensured through the use of specialized cold-chain transportation.

ETNB (89bio Pharma) Debt to Book Value history from 07/04/2022 to 11/15/2025

89bio Inc (ETNB) - metric breakdowns and financial figures

- price and consensus price forecast:

Stock Price 89bio, Inc.|ETNB - Analyst Consensus Forecast

- market capitalization data:

Market Value 89bio Pharma|ETNB - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share 89bio|ETNB - Company Net Assets|Market Capitalization to Book Value Ratio 89bio.com|ETNB - Company Total Assets

- debt and liquidity data:

Total Debt to Equity Ratio 89bio, Inc.|ETNB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity 89bio Corp|ETNB - Company Total Debt|Debts to Book Capitalization 89bio Pharma

Fundamental company analysis:89bio, Inc. - ETNB

This indicator determines the proportion of borrowed capital relative to the total value of assets minus liabilities, reflecting the extent to which the balance sheet structure depends on credit resources. For 89bio, Inc. (ETNB), the total debt-to-book capitalization ratio serves as a marker of financial stability when scaling operations with external research centers, where an increase in debt may indicate a search for liquidity to diversify the vendor pool.

Competitors of 89bio, Inc. (ETNB)